Resources

Patient Resources (by PBC Ireland)

📝 Clinic Visit Questionnaire (pdf)
Complete the form in advance, bring it with you to your clinic visit, and hand it to your consultant.
Use it as a guide to make sure everything you’ve ticked is discussed before you leave.

New PBC Drugs Monitor

(last checked: 25/5/2025)
Elafibranor (Iqirvo®) : Available ❌ | HSE HT Approval ❌ | NCPE (HTA ID: 25005)⌛ | IQIRVO (Ipsen) | EMA Approval ✅ | ELATIVE® Trial
Seladelpar (Lyvdelzi®) : Available ❌ | HSE HT Approval ❌ | NCPE (HTA ID: N)❌ | Lyvdelzi® (Gilead) | EMA Approval ✅ | ASSURE Trial, RESPONSE Trial

Investigational Therapies (in the pipeline)

There are several new drugs in early to mid-stage development for PBC. Some focus on relieving pruritus by reducing bile acid levels through inhibition of bile acid transport (IBAT). Others aim to address both cholestasis and metabolic dysfunction by targeting nuclear receptors (PPARα/γ) involved in lipid and bile acid metabolism. Additional candidates are designed to reduce liver inflammation and fibrosis, offering potential benefits in slowing disease progression.
(last checked: 2/6/2025)
• Volixibat (Mirum Pharmaceuticals): An IBAT inhibitor in Phase IIb trials. Shows strong anti-pruritic effects and bile acid reduction.
• Linerixibat (GlaxoSmithKline): An IBAT inhibitor in Phase III trials, focusing on alleviating pruritus associated with PBC.
• Saroglitazar (Zydus Lifesciences): A dual PPARα/γ agonist in Phase IIb/III trials. It targets both cholestasis and metabolic dysfunction in PBC.
• Cilofexor (Gilead Sciences): FXR agonist, Phase: II, Showed significant reductions in ALP, GGT, and CRP in patients not responding to UDCA, with a tolerable side-effect profile.
• Setanaxib (Genkyotex/Ipsen): NOX1/4 inhibitor. Phase: IIb/III. Targets liver fibrosis and inflammation, with early signs of efficacy in reducing fatigue and improving biochemical markers.

Tips for living with PBC

Primary Biliary Cholangitis (Irish Liver Foundation)
Living with primary biliary cholangitis (British Liver Trust)
Primary biliary cholangitis (PBC) - Living with your diagnosis (Canadian PBC Society)
Primary biliary cholangitis: Lifestyle do's and don'ts (Mayo Clinic)
Primary Biliary Cholangitis (PBC): Living With This Chronic Disease (Cleveland Clinic)

Diet and wellness tips

The PBC Diet: What to Eat, What to Avoid (American Liver Foudation)
Using Food To Manage Primary Biliary Cholangitis (Cleveland Clinic)
Primary biliary cholangitis: Your guide to diet and nutrition (Mayo Clinic)
Health Eating (Canadian PBC Society)

Useful Websites (Irish)

Beaumont Hospital (Hepatology Dept.)
Irish Liver Foundation
Mater Hospital (Centre for Liver Disease)
St. James' (Hepatology Centre)
St. Vincent's (Hepatology Dept.)
Liver Ireland Support Network (LISN)

Useful Websites (International)

PBC Foundation (UK)
PBCers (USA)
American Liver Foundation (USA)
Canadian PBC Society (Canada)
Cleveland Clinic (USA)

PBC in the News (The latest 5 articles from Google News)

28/01/2026 Could the sun lower PBC risk? Study explores benefits of UV exposure. - Liver Disease News

28/01/2026 Primary Biliary Cholangitis Therapeutics Market to Reach $1.36 Billion | Update by AMR - openPR.com

26/01/2026 Key Symptoms of PBC- Fatigue, Pruritus, and Bone Health - HCPLive

26/01/2026 Segment 1- An Overview of PBC Pathophysiology, Severity, and Burden - HCPLive

09/01/2026 Evaluating the clinical care, quality of life and overall experiences of patients with primary biliary cholangitis (PBC) during the pandemic: A Canadian mixed-methods study | PLOS One - PLOS

See All PBC in the News

Guidelines

Primary biliary cholangitis (PBC) - Living with your diagnosis (Canadian PBC Society)
Diagnosis and Treatment of Primary Biliary Cholangitis: A Patient‐Friendly Summary of the 2018 AASLD Practice Guidance
PBC primary biliary cholangitis treatment and management guidelines (the British Society of Gastroenterology/UK)
EASL Clinical Practice Guidelines: The Diagnosis and management of patients with Primary Biliary Cholangitis (Lay terms)
EASL Clinical Practice Guidelines: The Diagnosis and management of patients with Primary Biliary Cholangitis (Journal of Hepatology)

Publications (The latest 5 articles from PubMed)

Zhou X, et al. 2026. IGFBP4 is a Metric for Primary Biliary Cholangitis and Attenuates Biliary Epithelial Cell Injury. Liver Int (Mar 2026)

Eruzun H, Gronbaek H. 2026. Awareness of Primary Biliary Cholangitis Among Turkish Physicians: A Cross-Sectional, Multicenter, Web-Based Survey. J Clin Med (Jan 2026)

Yang M, et al. 2025. Identification of Differentially Expressed Genes and Molecular Pathways Involved in Primary Biliary Cholangitis Using RNA-Seq. Genes (Basel) (Dec 2025)

Sukubo NG, et al. 2026. Kupffer cell autophagy emerges as a central regulator of immune dysregulation in primary biliary cholangitis. Gut (Jan 2026)

Scarlata GGM, Abenavoli L. 2026. The role of gut microbiota in the pathogenesis of primary biliary cholangitis: an immunological perspective. Expert Rev Clin Immunol (Jan 2026)

See 100 Publications

Media

Press Contact: Gerry Nesbitt, gerry@PBCireland.org

Logo: 1024x1024.png 3064x3064.png Logo Black